More than 90% of patients continue to receive prescription opioids after overdose

NewsGuard 100/100 Score

More than 90 percent of patients with chronic pain continue to receive prescription opioids after an overdose and are at high risk for experiencing a repeated overdose, according to an article published in Annals of Internal Medicine.

Nonfatal opioid overdose is an opportunity to identify and treat substance use disorders, but treatment patterns after the overdose are unknown. Utilizing Optum, a large national commercial insurance claims database with data on 50 million individuals over a 12 year period, researchers identified nearly 3,000 patients who experienced a nonfatal overdose while taking opioids prescribed for chronic pain. The data showed 91 percent of those patients continued to be prescribed opioids after the overdose. In addition, 70 percent received prescriptions from the same provider who prescribed them opioids before their initial overdose. At two years follow up, patients who continued taking high dosages of opioids were twice as likely to have another overdose compared to those who discontinued opioid use after the overdose.

According to the authors, the findings highlight the challenges faced by physicians to balance the known risks with potential benefits of prescription opioids for patients with chronic pain. They say their research reinforces the importance of developing tools that will help better identify and treat patients at risk for opioid use disorders and/or overdose.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Vaccines targeting chronic diseases show promise in combatting age-related conditions